Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win
Immunome is seeking US approval for its gamma secretase inhibitor (GSI) for the treatment of desmoid tumours after the drug…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
InnoCare’s BTK inhibitor advances to Phase III in SLE
InnoCare Pharma’s orelabrutinib is progressing to a pivotal trial in systemic lupus erythematosus (SLE) after the drug displayed encouraging activity…
-
GRI Bio’s tazarotene achieves Phase IIa IPF success
GRI Bio’s lead candidate, tazarotene, has exhibited disease-modifying potential in a mid-stage study in idiopathic pulmonary fibrosis (IPF). In the…
-
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC
Bristol Myers Squibb (BMS) and BioNTech's pumitamig has displayed promising efficacy and safety during a mid-stage trial in front and…
-
ASH 2025: MSD’s B-ALL drug shows potential, but all patients experience AEs
MSD said its newly acquired T-cell engager has demonstrated acceptable tolerability and safety in relapsed or refractory B-cell acute lymphoblastic…
-
ASH 2025: Cullinan’s T-cell engager boasts potential across p53 AML subset
Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute…
-
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
Spinogenix’s lead candidate, tazbentetol, has shown early signs of sustained, cumulative cognitive benefits in patients with mild-to-moderate Alzheimer’s disease in…
-
AL-S takes mAb to Phase III after mid-stage ALS success
AL-S Pharma is planning a registrational study for its amyotrophic lateral sclerosis (ALS) monoclonal antibody (mAb), AP-101, after the drug…
-
ARCH-backed Paradigm snaps up Flatiron’s clinical research business
US-based clinical trial technology specialist Paradigm Health has agreed to purchase Roche-owned Flatiron Health’s clinical research division. Through this acquisition,…
-
Protara’s cell therapy touts BCG-naïve treatment potential in Phase II
Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in Bacillus Calmette-Guérin…